| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/16/2003 | WO2003003979A2 Methods for the production of purified recombinant human uteroglobin for the treatment of inflammatory and fibrotic conditions |
| 01/16/2003 | WO2003003975A2 Detection and therapy of vulnerable plaque with photodynamic compounds |
| 01/16/2003 | WO2003003906A2 Diagnostic and screening methods for bladder cancer |
| 01/16/2003 | WO2003003806A2 Dye-azide compounds for dual phototherapy |
| 01/16/2003 | WO2002094194A3 Compositions and methods for inhibiting metastasis |
| 01/16/2003 | WO2002085857A3 Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| 01/16/2003 | WO2002085387A3 A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent ans their use in the treatment of inflammatory skin conditions |
| 01/16/2003 | WO2002085386A3 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use to induce apoptosis in cancerous tissue |
| 01/16/2003 | WO2002085385A3 Medicament containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of diseases of the mucosa |
| 01/16/2003 | WO2002077023A3 A new essential downstream component of the wingless signalling pathway |
| 01/16/2003 | WO2002076930A3 Substituted diarylureas as stimulators for fas-mediated apoptosis |
| 01/16/2003 | WO2002072527A3 1-butyric acid derivatives such as carbomethoxypropionyl cyanide or leflunomide derivatives, and the therapeutic use thereof |
| 01/16/2003 | WO2002070467B1 Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments |
| 01/16/2003 | WO2002067968A3 14-3-3 binding molecules as sensitizers for anticancer therapies |
| 01/16/2003 | WO2002067893A3 Pharmaceutical formulation comprising bicalutamide |
| 01/16/2003 | WO2002043661A3 Recombinant anti-cd30 antibodies and uses thereof |
| 01/16/2003 | WO2002042445A3 Differentiated cells suitable for human therapy |
| 01/16/2003 | WO2002040540A3 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 01/16/2003 | WO2002040016A3 Association of calpain inhibitors and reactive oxygen species trapping agents |
| 01/16/2003 | WO2002038177A3 Adjuvant combination formulations |
| 01/16/2003 | WO2002038172A3 Sdf-1 beta expressing tumor cells as tumor vaccines |
| 01/16/2003 | WO2002034247A3 Anticancer agents based on regulation of protein prenylation |
| 01/16/2003 | WO2002033044A3 Methods of high-throughput screening for internalizing antibodies |
| 01/16/2003 | WO2002031109A3 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 01/16/2003 | WO2002028832A3 Diindolylmethane and c-substituted diindolylmethane compositions and methods for the treatment of multiple cancers |
| 01/16/2003 | WO2002026819A3 Recombinant bcg vaccines for the prevention and treatment of cancer |
| 01/16/2003 | WO2002026782A3 Antiangiogenic polypeptides and methods for inhibiting angiogenesis |
| 01/16/2003 | WO2002022808A3 Cripto mutant and uses thereof |
| 01/16/2003 | WO2002022806A3 Isolated human phospholipase proteins, nucleic acid molecules encoding human phospholipase proteins, and uses tehreof |
| 01/16/2003 | WO2002020813A3 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
| 01/16/2003 | WO2002016587A3 Microtubule-associated proteins and tubulins |
| 01/16/2003 | WO2002014352A3 Therapeutic compounds for ovarian cancer |
| 01/16/2003 | WO2002012196A3 Lactam compounds and their use as inhibitors of serine proteases and method |
| 01/16/2003 | WO2002011715A3 The use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 01/16/2003 | WO2002010406A3 Metalloproteinase-disintegrin polypeptides and methods of making and use thereof |
| 01/16/2003 | WO2002006465A3 7677, a novel human atpase family member and uses therefor |
| 01/16/2003 | WO2002004021A9 Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
| 01/16/2003 | WO2002002772A3 Human extracellular matrix (ecm)-related tumor marker |
| 01/16/2003 | WO2002002094A3 Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy |
| 01/16/2003 | WO2001098323A8 G-protein coupled receptors |
| 01/16/2003 | WO2001093913A3 T cell receptor fusions and conjugates and methods of use thereof |
| 01/16/2003 | WO2001092549A3 Method and composition for targeting an adenoviral vector |
| 01/16/2003 | WO2001092490A3 Isolated human aminotransferase proteins, nucleic acid molecules encoding human aminotransferase proteins, and uses thereof |
| 01/16/2003 | WO2001091739A3 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
| 01/16/2003 | WO2001090192A3 Bispecific immunoglobulin-like antigen binding proteins and method of production |
| 01/16/2003 | WO2001090156A3 Card domain containing polypeptides, encoding nucleic acids, and methods of use |
| 01/16/2003 | WO2001090136A3 Triterpenoid derivatives |
| 01/16/2003 | WO2001085941A9 Myc targets |
| 01/16/2003 | WO2001070174A8 Vegf-modulated genes and methods employing them |
| 01/16/2003 | WO2001068880A9 Estrogen-regulated myo-inositol phosphate synthase: compositions and methods of use |
| 01/16/2003 | WO2001064944A9 MODULATION OF PLEIOTROPHIN SIGNALING BY RECEPTOR-TYPE PROTEIN TYROSINE PHOSPHATASE β/$g(z) |
| 01/16/2003 | WO2001058954A9 Trade molecules and uses related thereto |
| 01/16/2003 | WO2001052868A9 Combinations for treating neoplasms |
| 01/16/2003 | WO2001051049A9 O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders |
| 01/16/2003 | WO1995032984A8 New lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs |
| 01/16/2003 | US20030013889 Process for the preparation of taxane derivatives |
| 01/16/2003 | US20030013886 Such as (E)-1-(2-Pyridyl)-2-styryl-1H-benzimidazole; antiinflammatory and analgesic agents; prostaglandin inhibitors |
| 01/16/2003 | US20030013861 E-isomeric fullerene derivatives |
| 01/16/2003 | US20030013771 Concurrent administering with drug; side effect reduction; central nervous system disorders |
| 01/16/2003 | US20030013766 Methods and pharmaceutical compositions for treatment of anti-estrogen resistant breast cancer using RXR Modulators |
| 01/16/2003 | US20030013759 Injection fatty acid, or salt thereof, into arteries |
| 01/16/2003 | US20030013757 Aromatic dicarboxylic acid derivatives |
| 01/16/2003 | US20030013756 Hormone inhibitor; sexual disorders |
| 01/16/2003 | US20030013754 Antiinflamamtory agents |
| 01/16/2003 | US20030013752 Controlling dosage cycles |
| 01/16/2003 | US20030013745 Urazole compounds useful as anti-inflammatory agents |
| 01/16/2003 | US20030013739 Synergistic mixtures; side effect reduction |
| 01/16/2003 | US20030013737 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections |
| 01/16/2003 | US20030013731 Synergistic mixtures; enhanced absorption |
| 01/16/2003 | US20030013723 Novel urokinase inhibitors |
| 01/16/2003 | US20030013718 Phthalazine derivatives for treating inflammatory diseases |
| 01/16/2003 | US20030013713 Compounds as PDE IV and TNF-inhibitors |
| 01/16/2003 | US20030013704 Adamantane derivatives |
| 01/16/2003 | US20030013702 Agents and methods for treatment of cancer |
| 01/16/2003 | US20030013691 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds |
| 01/16/2003 | US20030013682 Heparins; antiutmor agents |
| 01/16/2003 | US20030013681 Complexing with galectins |
| 01/16/2003 | US20030013674 Gene therapy; in situ supplying of genes; nucleic acid complex |
| 01/16/2003 | US20030013668 Antiarthritic agents; inflammatory bowel disease; multiple sclerosis |
| 01/16/2003 | US20030013660 Dioxolane analogs for improved inter-cellular delivery |
| 01/16/2003 | US20030013638 P27 prevents cellular migration |
| 01/16/2003 | US20030013191 Transgenic cells for use in human therapeutics and diagnostics |
| 01/16/2003 | US20030013170 Inhibitors of receptor activator of NF-kappaB and uses thereof |
| 01/16/2003 | US20030013144 Detection of modulator of cancer activity; obtain sample containing biopolymers, incubate with modulator, monitor cellular response |
| 01/16/2003 | US20030013122 Methods and compositions for using MHC class II invariant chain polypeptide as a receptor for macrophage migration inhibitory factor |
| 01/16/2003 | US20030013097 Genes overexpressed in prostate disorders as diagnostic and therapeutic targets |
| 01/16/2003 | US20030013095 Nuclcic acid enzyme for use in the prevention and treatment of infections and cancer |
| 01/16/2003 | US20030013081 Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
| 01/16/2003 | US20030013077 Binding to monoclonal antibodies; detection of Kaposi's sarcoma |
| 01/16/2003 | US20030012819 Method of preparing biological materials and preparations produced using same |
| 01/16/2003 | US20030012812 Inhibition of bcl-2 protein expression by liposomal antisense oligodeoxynucleotides |
| 01/16/2003 | US20030012806 Drug releasing elastic band and method |
| 01/16/2003 | US20030012798 Physiologically active substance eem-s originating in mushroms, process for producing the same and drugs |
| 01/16/2003 | US20030012794 Kits comprising heat shock protein-antigenic molecule complexes |
| 01/16/2003 | US20030012785 Intracellular drug delivery into an interleukin-2 receptor-bearing cell includes a chemical agent and a copy of an interleukin-2-receptor binding and endocytosis-inducing ligand bound to a water soluble polymer |
| 01/16/2003 | US20030012783 Interfere with the binding of a tumor necrosis factor receptor with its ligand; inhibiting the proliferation of tumor cells |
| 01/16/2003 | US20030012782 Method and composition for altering a T cell mediated pathology |
| 01/16/2003 | US20030012776 A nucleic acid sequence which encodes RIAZ protein; abolishing drug resistance in cancer cells; drug development assay; diagnosing and treating cancer; gene therapy; prediction of chemosensitivity in cancer patients |
| 01/16/2003 | US20030012775 PEG conjugates of NK4 |
| 01/16/2003 | US20030012770 Recombinant p53 adenovirus methods and compositions |